These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18341192)

  • 1. Assessment of the pharmaceutical quality of omeprazole capsule brands marketed in Egypt.
    El-Sayed A; Boraie NA; Ismail FA; El-Khordagui LK; Khalil SA
    East Mediterr Health J; 2007; 13(6):1427-37. PubMed ID: 18341192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissolution test for liquid formulations of omeprazole enteric-coated products.
    Jang HJ; Kang BC; Shin WG; Lee S
    Ann Pharmacother; 2003 Jan; 37(1):150-1. PubMed ID: 12503954
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro evaluation of dissolution properties and degradation products of omeprazole in enteric-coated pellets.
    Storpirtis S; Rodrigues D
    Drug Dev Ind Pharm; 1998 Nov; 24(11):1101-7. PubMed ID: 9876567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omeprazole--a new formulation.
    Armstrong D
    Can J Gastroenterol; 1997; 11(8):655-6. PubMed ID: 9459043
    [No Abstract]   [Full Text] [Related]  

  • 5. Generic omeprazole delayed-release capsules: in vitro performance evaluations.
    Moore T; Smith A; Ye W; Toler DY; Westenberger BJ; Lionberger R; Raw A; Yu L; Buhse LF
    Drug Dev Ind Pharm; 2009 Aug; 35(8):917-21. PubMed ID: 19555236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissolution of omeprazole from delayed-release solid oral dosage forms.
    Farinha A; Bica A; Martins JM; Pais JP
    Drug Dev Ind Pharm; 2000 Jul; 26(7):785-90. PubMed ID: 10872100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of capsules containing omeprazole in enteric coated pellets.
    Palummo M; Cingolani A; Dall L; Volonté MG
    Boll Chim Farm; 2000; 139(3):124-8. PubMed ID: 10961022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
    Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A
    Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Differences in the release of omeprazole in 4 commercial preparations: influence of pH and ionic concentration].
    Navarro MA; Raei N; Torres F; Granero L; García-Zaragoza E; Esplugues JV; Esteban Peris J
    Gastroenterol Hepatol; 1998 Feb; 21(2):63-70. PubMed ID: 9549180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro study on capsule formulations of omeprazole containing enteric coated granules.
    Pandey VP; Phanindrudu A; Manavalan R; Livingston J
    Boll Chim Farm; 2002; 141(6):419-22. PubMed ID: 12577509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bioavailability of three brands of omeprazole capsule and their effects on 24 hour intragastric pH in healthy volunteers].
    Dong H
    Zhonghua Nei Ke Za Zhi; 1999 Aug; 38(8):533-6. PubMed ID: 11798692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.
    Thomson AB; Kirdeikis P; Lastiwka R; Röhss K; Sinclair P; Olofsson B
    Can J Gastroenterol; 1997; 11(8):657-60. PubMed ID: 9459044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preformulation studies for generic omeprazole magnesium enteric coated tablets.
    Migoha CO; Ratansi M; Kaale E; Kagashe G
    Biomed Res Int; 2015; 2015():307032. PubMed ID: 25699270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment.
    Meissner S; Bansal M; Dela CPD; Hanning S; Svirskis D
    Int J Pharm Compd; 2020; 24(2):140-147. PubMed ID: 32196476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a bionic system for the simultaneous prediction of the release/absorption characteristics of enteric-coated formulations.
    Liu W; He X; Li Z; Gao X; Ma Y; Xun M; Liu C
    Pharm Res; 2013 Feb; 30(2):596-605. PubMed ID: 23135820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the composition of a fixed dose combination on bioequivalence results.
    Šalandová J; Franc A; Hofmann J; Dumicic A; Kukačková L; Červená T; Beránek J; Srbek J; Repický A; Vladovičová B; Vetchý D
    Int J Pharm; 2018 Jul; 546(1-2):235-246. PubMed ID: 29758343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid state interactions between the proton pump inhibitor omeprazole and various enteric coating polymers.
    Stroyer A; McGinity JW; Leopold CS
    J Pharm Sci; 2006 Jun; 95(6):1342-53. PubMed ID: 16625655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical Equivalence and Quality Assessment of Various Brands of Gastro-Resistant Omeprazole Capsules in the Kumasi Metropolis.
    Osei YA; Oppong Boakye E; Bayor MT; Akuffo Owusu FW
    ScientificWorldJournal; 2022; 2022():7924600. PubMed ID: 36408195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.
    Sharma VK
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S18-21. PubMed ID: 10597120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation study for lansoprazole fast-disintegrating tablet. II. Effect of triethyl citrate on the quality of the products.
    Shimizu T; Kameoka N; Iki H; Tabata T; Hamaguchi N; Igari Y
    Chem Pharm Bull (Tokyo); 2003 Sep; 51(9):1029-35. PubMed ID: 12951443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.